同时治疗银屑病及银屑病型关节炎的生物及小分子药物研究进展

在银屑病的发病过程中,约1/4的患者会并发银屑病型关节炎的临床表现,如果能有一种药物可以同时作用于银屑病皮肤和关节,那么无疑对患者是有益的.目前新兴的生物药物包括:肿瘤坏死因子抑制剂,如阿达木单抗、伊那西普、英夫利昔单抗、戈利木单抗和赛妥珠单抗;抗IL-12/IL-23 p40药物,如乌司奴单抗;抗IL-17药物,包括苏金单抗、brodalumab.它们都对银屑病和银屑病型关节炎有良好的临床疗效和安全性.最近,另有一些小分子化学物质应运而生,如磷酸二酯酶4抑制剂阿瑞米拉和JAK抑制剂托法替尼、INCB018424等,它们都有一定的治疗意义.本文就能够同时治疗银屑病、银屑病型关节炎的生物及小分子药物作一综述.

Biologic and small molecular agents for simultaneous treatment of psoriasis and psoriatic arthritis: research progress

In the process of the pathogenesis of psoriasis about a quarter of the clinical manifestations of patients with psoriatic arthritis. If we can have a preparation can be used at the same time to the skin and joint symptoms, would be beneficial for patients. At present, we found that for both effective drugs: biologic agents, the tumor necrosis factor inhibitors such as adalimumab, etanercept, infliximab, golimumab and certolizumab; anti-IL-12p40 antibodies such as ustekinumab; anti-IL-17 agents consist of secukinumab, brodalumab. Recently, another small molecule agents arise at the historic moment, such as phosphodiesterase-4 inhibitor, apremilast, as well as the oral Jak inhibitor, tofacitinib and INCB018424 have a certain treatment significance. This review paper provides a good overview of the agents that can be used for the concurrent management of skin and joint psoriasis.